Payment overview · 2025
General Payments
$1,692.23
9 reported records · 4 companies
Healthcare provider profile · identity verified
Timothy D Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HUNTSVILLE, TN · NPI 1720021660
Verified facts
What the public records show
CMS Open Payments records show Timothy D Smith, M.D. received $1,692.23 in general payments during 2025 across 9 reported records.
Boston Scientific Corporation accounted for 95.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,611.53 | 95.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.36 | 2.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.48 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.86 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,535.21 | 4 |
| Food and Beverage | $157.02 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,611.53 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 206 |
| Gabapentin | Gabapentin | 431 | 106 |
| Potassium Chloride | Potassium Chloride | 408 | 141 |
| Omeprazole | Omeprazole | 374 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 107 |
| Losartan Potassium | Losartan Potassium | 283 | 90 |
| Benazepril Hcl | Benazepril Hcl | 265 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 82 |
| Buspirone Hcl | Buspirone Hcl | 227 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 82 |
| Ezetimibe | Ezetimibe | 196 | 69 |
| Tramadol Hcl | Tramadol Hcl | 195 | 67 |
| Metformin Hcl | Metformin Hcl | 192 | 66 |
| Eliquis | Apixaban | 187 | 44 |
| Furosemide | Furosemide | 176 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 58 |
| Sertraline Hcl | Sertraline Hcl | 175 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 51 |
| Famotidine | Famotidine | 146 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 45 |
| Lisinopril | Lisinopril | 139 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 49 |
| Metformin Hcl Er | Metformin Hcl | 131 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 33 |
| Allopurinol | Allopurinol | 114 | 41 |
| Carvedilol | Carvedilol | 111 | 35 |
| Lorazepam | Lorazepam | 111 | 25 |
| Spironolactone | Spironolactone | 111 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 35 |
| Memantine Hcl | Memantine Hcl | 101 | 25 |
| Trazodone Hcl | Trazodone Hcl | 95 | 31 |
| Meloxicam | Meloxicam | 89 | 28 |
| Montelukast Sodium | Montelukast Sodium | 89 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 24 |
| Azelastine Hcl | Azelastine Hcl | 83 | 48 |
| Azithromycin | Azithromycin | 83 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 31 |
| Ozempic | Semaglutide | 74 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 60 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 27 |
| Clonazepam | Clonazepam | 65 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | 16 |
| Warfarin Sodium | Warfarin Sodium | 62 | 14 |
| Enalapril Maleate | Enalapril Maleate | 60 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 35 |
| Trulicity | Dulaglutide | 56 | 16 |
| Atenolol | Atenolol | 55 | 18 |
| Alprazolam | Alprazolam | 53 | 12 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 49 | 20 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Simvastatin | Simvastatin | 47 | 13 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Ondansetron Odt | Ondansetron | 46 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 20 |
| Fenofibrate | Fenofibrate | 43 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Jardiance | Empagliflozin | 40 | 11 |
| Nystatin | Nystatin | 40 | 28 |
| Methylprednisolone | Methylprednisolone | 39 | 39 |
| Sucralfate | Sucralfate | 39 | 17 |
| Methocarbamol | Methocarbamol | 38 | 14 |
| Hydrocortisone | Hydrocortisone | 34 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Levofloxacin | Levofloxacin | 33 | 29 |
| Pregabalin | Pregabalin | 33 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 20 |
| Clonidine Hcl | Clonidine Hcl | 30 | 13 |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Naproxen | Naproxen | 29 | 15 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 11 |
| Ramipril | Ramipril | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 22 |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Estradiol | Estradiol | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | 11 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,692.23 · 9 records | Boston Scientific Corporation | General - Therapies, Ozempic, SHINGRIX, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error